- Home
- MRNA vs NWSA Comparison
MRNA vs NWSA Comparison
Compare MRNA & NWSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNA
- NWSA
- Stock Information
- Founded
- MRNA 2010
- NWSA 2012
- Country
- MRNA United States
- NWSA United States
- Employees
- MRNA N/A
- NWSA N/A
- Industry
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- NWSA Newspapers/Magazines
- Sector
- MRNA Health Care
- NWSA Consumer Discretionary
- Exchange
- MRNA Nasdaq
- NWSA Nasdaq
- Market Cap
- MRNA 16.5B
- NWSA 16.1B
- IPO Year
- MRNA 2018
- NWSA N/A
- Fundamental
- Price
- MRNA $36.85
- NWSA $28.62
- Analyst Decision
- MRNA Hold
- NWSA Strong Buy
- Analyst Count
- MRNA 17
- NWSA 5
- Target Price
- MRNA $87.67
- NWSA $36.25
- AVG Volume (30 Days)
- MRNA 8.4M
- NWSA 2.7M
- Earning Date
- MRNA 11-07-2024
- NWSA 11-07-2024
- Dividend Yield
- MRNA N/A
- NWSA 0.70%
- EPS Growth
- MRNA N/A
- NWSA 158.28
- EPS
- MRNA N/A
- NWSA 0.62
- Revenue
- MRNA $5,081,000,000.00
- NWSA $10,163,000,000.00
- Revenue This Year
- MRNA N/A
- NWSA $5.43
- Revenue Next Year
- MRNA N/A
- NWSA $3.55
- P/E Ratio
- MRNA N/A
- NWSA $46.17
- Revenue Growth
- MRNA N/A
- NWSA 2.66
- 52 Week Low
- MRNA $35.80
- NWSA $20.91
- 52 Week High
- MRNA $170.47
- NWSA $30.04
- Technical
- Relative Strength Index (RSI)
- MRNA 12.62
- NWSA 61.09
- Support Level
- MRNA $41.54
- NWSA $28.54
- Resistance Level
- MRNA $56.70
- NWSA $29.58
- Average True Range (ATR)
- MRNA 2.95
- NWSA 0.63
- MACD
- MRNA -1.05
- NWSA 0.11
- Stochastic Oscillator
- MRNA 4.80
- NWSA 60.66
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About NWSA News Corporation
News Corporation is a diversified media conglomerate with significant presence in the us, the UK, and Australia. Key mastheads include The Wall Street Journal, Barron's, New York Post, The Times, The Sun, The Australian, Herald Sun, and The Daily Telegraph. The company also has a strong presence in the Australian subscription video market through 65%-owned Foxtel, and streaming platforms such as sport-focused Kayo and entertainment-focused Binge. Its 61%-owned REA Group is the dominant property listings business in Australia. In addition, it owns Harper Collins, one of the biggest book publishers in the world, and has a sizable us digital property advertising business, Move.